Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7927543 | 0.81 | HSD11B1 (0.48) | HSD11B1EPHX1EPHX2CYP2C9FKBP1A | |
| SCHEMBL5350579 | 0.80 | HSD11B1 (0.52) | HSD11B1EPHX1EPHX2CYP2C9FKBP1A | |
| SCHEMBL3753073 | 0.78 | HSD11B1 (0.50) | HSD11B1EPHX1EPHX2CYP2C9FKBP1A | |
| SCHEMBL1155595 | 0.78 | HSD11B1 (0.50) | HSD11B1EPHX1EPHX2CYP2C9FKBP1A | |
| SCHEMBL6670021 | 0.78 | HSD11B1 (0.50) | HSD11B1EPHX1EPHX2CYP2C9FKBP1A | |
| SCHEMBL21392343 | 0.78 | HSD11B1 (0.46) | HSD11B1EPHX1EPHX2CYP2C9FKBP1A | |
| SCHEMBL7927539 | 0.78 | HSD11B1 (0.46) | HSD11B1EPHX1EPHX2CYP2C9FKBP1A | |
| SCHEMBL3905357 | 0.78 | HSD11B1 (0.46) | HSD11B1EPHX1EPHX2CYP2C9FKBP1A | |
| SCHEMBL24361096 | 0.76 | HSD11B1 (0.48) | HSD11B1EPHX1EPHX2CYP2C9FKBP1A | |
| SCHEMBL9016086 | 0.76 | HSD11B1 (0.40) | HSD11B1EPHX1EPHX2CYP2C9HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110627832-A | Preparation method for synthesizing tenofovir alafenamide by oxidation method | 江西农业大学 | 2019-12-31 | — | — | CN | claimed |
| CN-110627832-A | Preparation method for synthesizing tenofovir alafenamide by oxidation method | 江西农业大学 | 2019-12-31 | — | — | CN | disclosed |
| US-20190047939-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF 17(20)-ENE B-SECO STEROIDS | PATHEON AUSTRIA GMBH & CO KG (AU) | 2019-02-14 | — | — | US | disclosed |
| CN-109219612-A | Prepare 17 (20)-alkene B- open loop steroids method and intermediate | 帕西昂奥地利有限两合公司 | 2019-01-15 | — | — | CN | disclosed |
| EP-3423465-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF 17(20)-ENE B-SECO STEROIDS | Patheon Austria GmbH & Co KG (AT) | 2019-01-09 | — | — | EP | disclosed |
| US-9163012-B2 | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163012-B2 | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163012-B2 | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| WO-1991019733-A1 | DERIVATIVES OF TETRAPEPTIDES AS CCK AGONISTS | ABBOTT LABORATORIES (US) | 1991-12-26 | — | — | WO | disclosed |
| WO-1991000274-A1 | N-SUBSTITUTED CYCLOALKYL AND POLYCYCLOALKYL ALPHA-SUBSTITUTED TRP-PHE- AND PHENETHYLAMINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1991-01-10 | — | — | WO | disclosed |
| EP-0405537-A1 | N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives | WARNER-LAMBERT COMPANY (US) | 1991-01-02 | — | — | EP | disclosed |
| US-4591583-A | TREATING VIRAL INFECTIONS | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1986-05-27 | — | — | US | disclosed |
| US-4501741-A | BENZOTHIOPHENE-SUBSTITUTED | ELI LILLY AND COMPANY (US) | 1985-02-26 | — | — | US | disclosed |
| EP-0122158-A2 | Improvements in or relating to benzothienyl cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1984-10-17 | — | — | EP | disclosed |
| US-4386081-A | VIRICIDE | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1983-05-31 | — | — | US | disclosed |
| EP-0003007-B1 | ALIPHATIC DERIVATIVES OF PHOSPHONOFORMIC ACID, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COMBATING VIRUS INFECTIONS | Astra Läkemedel Aktiebolag (SE) | 1982-04-07 | — | — | EP | disclosed |
| EP-0003007-A2 | Aliphatic derivatives of phosphonoformic acid, pharmaceutical compositions and methods for combating virus infections | Astra Läkemedel Aktiebolag (SE) | 1979-07-11 | — | — | EP | disclosed |
| US-3936491-A | Adamantylene compounds | U.S. PHILIPS CORPORATION (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047939-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF 17(20)-ENE B-SECO STEROIDS | CYP17A1, CYP46A1, HSD17B7 | HSD11B1 7/4885EPHX1 144/4885EPHX2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.